|1.||Dorsey, Grant: 28 articles (01/2015 - 05/2006)|
|2.||Rosenthal, Philip J: 24 articles (01/2015 - 05/2006)|
|3.||White, Nicholas J: 20 articles (10/2015 - 10/2004)|
|4.||Kamya, Moses R: 20 articles (01/2015 - 05/2006)|
|5.||Mårtensson, Andreas: 15 articles (10/2014 - 10/2005)|
|6.||Björkman, Anders: 13 articles (10/2014 - 10/2005)|
|7.||Ogutu, Bernhards: 12 articles (08/2015 - 01/2008)|
|8.||Lefèvre, Gilbert: 12 articles (01/2015 - 03/2002)|
|9.||Lindegardh, Niklas: 12 articles (09/2012 - 11/2004)|
|10.||Sowunmi, Akintunde: 11 articles (01/2015 - 08/2007)|
08/01/1999 - "The lumefantrine component is absorbed variably in malaria, and is eliminated more slowly (half-life of 3 to 6 days). "
01/01/2015 - "The predictive model through simulation of lumefantrine exposure at different dosage regimen scenarios for patients on EFV-based ART, suggest that AL taken twice daily for five days using the current dose could improve lumefantrine exposure and consequently malaria treatment outcomes. "
01/01/2013 - "Participants anticipated the public losing confidence in SP for IPTp after government announced artemither-lumefantrine (ALu) as the new first-line drug for uncomplicated malaria replacing SP. Role of private healthcare staff in IPTp services was acknowledged cautiously because CHMTs rarely supplied private clinics with SP for free delivery in fear that clients would be required to pay for the SP contrary to government policy. "
12/01/2011 - "The primary outcome was observed day 7 lumefantrine concentrations, as these are associated with therapeutic response in malaria. "
11/01/2011 - "For lumefantrine, the median AUC(0-∞) (459,980 μg · h/liter) was also similar to that in adults with malaria. "
|2.||Falciparum Malaria (Plasmodium falciparum Malaria)
03/01/2012 - "This study was conducted to correlate blood concentrations of lumefantrine with treatment outcome for patients with Plasmodium falciparum malaria when the drug was given without specific instructions for administration with food. "
09/01/2009 - "The objective of this study was to determine the population pharmacokinetic properties of lumefantrine in pregnant women with uncomplicated multidrug-resistant Plasmodium falciparum malaria on the northwestern border of Thailand. "
10/01/2015 - "Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border."
01/01/2014 - "[The management of therapeutic failure in a falciparum malaria patient under oral arthemether-lumefantrine therapy]."
09/01/2013 - "The physicochemical properties of lumefantrine, a first line combination medicine for the treatment of uncomplicated falciparum malaria have been determined experimentally rather than theoretically as a guide to understanding its disposition in human. "
09/01/2008 - "Patients with plasma lumefantrine concentrations < 280 ng/ml at Day 7 were at greater risk for re-infection (relative risk 5.62; P=0.027). "
01/01/2006 - "There were no recrudescences in either arm, but decreasing lumefantrine dose per Kg resulted in up to 13-fold higher adjusted risks of re-infection. "
01/01/2006 - "Predictors of lumefantrine concentrations were analysed to show how both C [lum]day7 and the weight-adjusted lumefantrine dose affect 28-day recrudescence and re-infection risks. "
09/01/2013 - "HIV-positive nigerian adults harbor significantly higher serum lumefantrine levels than HIV-negative individuals seven days after treatment for Plasmodium falciparum infection."
06/01/2013 - "Multicenter and randomized trials, however, are needed for a better understanding of the efficacy of artemether-lumefantrine against schistosome infection with ranges of intensity."
01/01/2015 - "Recrudescence was associated with low day 7 lumefantrine concentrations (HR 1.59 (95% CI 1.36 to 1.85) per halving of day 7 concentrations) and high baseline parasitemia (HR 1.87 (95% CI 1.22 to 2.87) per 10-fold increase). "
09/01/2013 - "Associations between day 7 levels of lumefantrine and risk of persistent parasitemia could not be evaluated due to inadequate power. "
08/01/2007 - "Artemether-lumefantrine clears parasitemia more rapidly than ASP but both combinations are effective in treatment of uncomplicated P. "
12/01/2014 - "Limitations included the exclusion of 11% of randomized patients with sub-threshold parasitemias on confirmatory microscopy and direct observation of only morning artemether-lumefantrine dosing. "
10/01/2014 - "It was found that the lumefantrine lipid emulsion (LUM-LE) and artemether-lumefantrine lipid emulsion (ARM-LUM-LE-3) (1:6) began to decrease the parasitemia levels after only 3 days, and the parasitemia inhibition was 90% at doses of 0.32 and 0.27 mg/kg, respectively, with immediate antimalarial effects greater than those of the positive-control group and constant antimalarial effects over 30 days. "
01/01/2012 - "Efficacy of artemether-lumefantrine as a treatment for uncomplicated Plasmodium vivax malaria in eastern Sudan."
12/01/2014 - "Artemisinin-naphthoquine should have greater activity in vivax malaria because the elimination of naphthoquine is slower than that of lumefantrine. "
12/01/2011 - "The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria."
08/01/2015 - "Quantitative magnetic fractionation and a published mathematical model were used to characterize between-treatment differences in gametocyte density and prevalence in 70 Papua New Guinean children with uncomplicated Plasmodium falciparum and/or Plasmodium vivax malaria randomized to one of two artemisinin combination therapies (artemether-lumefantrine or artemisinin-naphthoquine) in an intervention trial. "
01/01/2012 - "vivax malaria received artemether-lumefantrine (AL) tablets (containing 20mg artemether and 120 mg lumefantrine) and were monitored for 28 days. "
|9.||artemether-lumefantrine combination (Coartem)
|3.||Drug Therapy (Chemotherapy)